Profil
Dawn Hill has held a Non-Executive Director position at MAP Patient Access Ltd since 2012.
Additionally, she is the founder of MAP Patient Access Ltd, which was founded in 2012.
Aktive Positionen von Dawn Hill
| Unternehmen | Position | Beginn |
|---|---|---|
MAP Patient Access Ltd.
 MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022. | Gründer | 01.01.2012 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
MAP Patient Access Ltd.
MAP Patient Access Ltd. Miscellaneous Commercial ServicesCommercial Services MAP Patient Access Ltd. is a consultancy firm that provides market access, policy, public affairs, and legal projects to over 160 health tech companies and patient groups. MAP Patient Access is based in Cambridge, UK, and was founded in 2012 by Christian Hill and Dawn Hill. The British company offers services such as advance product notifications, payer engagement, budgeting, and treatment pathways. The company has worked on various projects, including supporting a growing US biopharma company in navigating product reimbursement across the EU5 and helping patients with life-threatening or seriously debilitating conditions access medicines through the Early Access to Medicines Scheme (EAMS). Daniel John Spacie has been the CEO of the company since 2022. | Commercial Services |
